(89Zr)Zr-Atezolizumab clinical trials

Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer

This study looks at a new way to scan for breast cancer using a special dye and a PET/CT scan. It compares this new scan with a standard test to see how well they match. The goal is to better understand and treat advanced triple-negative breast cancer.